BeOne Medicines AG (ONC)
ONC Stock Price Chart
Explore BeOne Medicines AG interactive price chart. Choose custom timeframes to analyze ONC price movements and trends.
ONC Company Profile
Discover essential business fundamentals and corporate details for BeOne Medicines AG (ONC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Feb 2016
Employees
12.00k
Website
https://beonemedicines.comCEO
John V. Oyler
Description
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
ONC Financial Timeline
Browse a chronological timeline of BeOne Medicines AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $1.57, while revenue estimate is $1.61bn.
Earnings released on 6 May 2026
EPS came in at $1.96 surpassing the estimated $0.73 by +168.49%, while revenue for the quarter reached $1.51bn , beating expectations by +5.35%.
Earnings released on 26 Feb 2026
EPS came in at $0.58 falling short of the estimated $1.60 by -63.75%, while revenue for the quarter reached $1.50bn , beating expectations by +2.24%.
Earnings released on 6 Nov 2025
EPS came in at $1.09 surpassing the estimated $0.72 by +51.39%, while revenue for the quarter reached $1.41bn , missing expectations by -2.72%.
Earnings released on 6 Aug 2025
EPS came in at $0.84 surpassing the estimated $0.48 by +75.00%, while revenue for the quarter reached $1.32bn , missing expectations by -8.82%.
Earnings released on 7 May 2025
EPS came in at $1.22 surpassing the estimated -$0.71 by +271.83%, while revenue for the quarter reached $1.12bn , missing expectations by -10.36%.
Earnings released on 27 Feb 2025
EPS came in at -$1.43 falling short of the estimated -$0.88 by -62.50%, while revenue for the quarter reached $1.13bn , beating expectations by +8.53%.
Earnings released on 12 Nov 2024
EPS came in at -$1.15 falling short of the estimated -$0.88 by -30.68%, while revenue for the quarter reached $1.00bn .
Earnings released on 7 Aug 2024
EPS came in at -$1.15 surpassing the estimated -$2.10 by +45.24%, while revenue for the quarter reached $929.17m .
Earnings released on 31 Mar 2024
EPS came in at -$2.41 , while revenue for the quarter reached $751.65m .
Earnings released on 31 Dec 2023
EPS came in at -$25.53 , while revenue for the quarter reached $634.41m .
Earnings released on 30 Sept 2023
EPS came in at $2.01 , while revenue for the quarter reached $781.31m .
Earnings released on 30 Jun 2023
EPS came in at -$3.64 , while revenue for the quarter reached $595.26m .
Earnings released on 31 Mar 2023
EPS came in at -$3.34 , while revenue for the quarter reached $447.80m .
Earnings released on 31 Dec 2022
EPS came in at -$30.54 , while revenue for the quarter reached $380.10m .
Earnings released on 30 Sept 2022
EPS came in at -$5.39 , while revenue for the quarter reached $387.63m .
Earnings released on 30 Jun 2022
EPS came in at -$5.56 , while revenue for the quarter reached $341.57m .
Earnings released on 31 Mar 2022
EPS came in at -$4.24 , while revenue for the quarter reached $306.63m .
Earnings released on 31 Dec 2021
EPS came in at -$6.16 , while revenue for the quarter reached $213.98m .
Earnings released on 30 Sept 2021
EPS came in at -$4.46 , while revenue for the quarter reached $206.44m .
ONC Stock Performance
Access detailed ONC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
